Using personalized therapy (administration of celecoxib to 70 carriers of the CYP2C9 NM genotype at an average dose of 200 mg /day once, to 32 carriers of the aceclofenac PM genotype 200 mg /day in two doses) aids to attain a better result like decrease in pain intensity, an improvement in the major indicators of quality of life, while ensuring safety and minimizing CPD, by reducing the gastrointestinal tract and cardiovascular system complications.

This study aimed to investigate the quality of life of people having chronic pelvic pain syndrome (CPPS) before and after prescription of non-steroidal anti-inflammatory drugs (NSAIDs), depending on the severity of the pain syndrome, the presence of comorbid pathology, the CYP2C9 genotype that assesses the rate of the metabolic reactions and risk of side effects.

In CPPS people, the carriage of variants of CYP2C9 gene mutations was explored (mean age 49.7 ± 13.43 years, men - 71, women – 81). Considering the presence of comorbid pathology and the outcomes of pharmacogenetic testing, personalized therapy with NSAIDs was chosen. The intensity of pain syndrome (visual analogue scale [VAS]), the quality of life (World Health Organization  Brief Questionnaire [WHOQOL BREF]), and the concentration of pro-inflammatory cytokines (interleukin-1β, interleukin-6) was estimated prior to initiation of treatment and on the 7th day of NSAID treatment.

With personalized treatment, a considerable decline in pain intensity and level of pro-inflammatory cytokines in the blood, and a rise in the quality of life of participants was noted in all the observation groups. In addition, in individuals receiving personalized therapy with NSAIDs, minimum development of undesirable adverse reactions was noted.